Inventor · disambiguated record
Janet Peper
Also filed as: PEPER JANET
27 granted patents·12 pending applications·122 citations·filing 2016–2023
97Inventor score
Top patents by PatentIndex Score
39 records- 0199US11278571B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 22, 2022·8 cites·20 claims
- 0299US11246889B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 15, 2022·5 cites·20 claims
- 0399US11071756B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 27, 2021·5 cites·20 claims
- 0499US10888587B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 12, 2021·8 cites·20 claims
- 0599US10881690B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 5, 2021·8 cites·20 claims
- 0699US10869897B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Dec 22, 2020·8 cites·20 claims
- 0799US10722538B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 28, 2020·8 cites·20 claims
- 0898US11214608B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jan 4, 2022·6 cites·20 claims
- 0998US11078253B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Aug 3, 2021·5 cites·20 claims
- 1098US11053296B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 6, 2021·5 cites·20 claims
- 1198US10639332B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted May 5, 2020·8 cites·20 claims
- 1297US11248035B1Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 15, 2022·3 cites·20 claims
- 1397US9889159B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Feb 13, 2018·16 cites·22 claims
- 1496US10639331B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted May 5, 2020·8 cites·20 claims
- 1596US10568909B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Feb 25, 2020·8 cites·20 claims
- 1696US10463696B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Nov 5, 2019·11 cites·20 claims
- 1792US11819518B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Nov 21, 2023·1 cites·20 claims
- 1887US2024076349A1Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 1987US2023241107A1Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 2087US2024034769A1Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 2187US2023201259A1Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 2287US2023241106A1Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 2387US2023086100A1Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 2487US2023312680A1Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 2587US2023365651A1Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 2687US2023285458A1Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 2787US2023190813A1Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 2883US10738100B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Aug 11, 2020·1 cites·21 claims
- 2982US11806366B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Nov 7, 2023·0 cites·20 claims
- 3081US12065477B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 20, 2024·0 cites·20 claims
- 3181US11919940B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 5, 2024·0 cites·20 claims
- 3281US11345737B1Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted May 31, 2022·0 cites·20 claims
- 3380US11858978B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jan 2, 2024·0 cites·20 claims
- 3479US11840562B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Dec 12, 2023·0 cites·20 claims
- 3579US2021106624A1Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Application pending·0 cites
- 3678US12098183B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Sep 24, 2024·0 cites·20 claims
- 3772US10899820B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 26, 2021·0 cites·20 claims
- 3872US10781244B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Sep 22, 2020·0 cites·20 claims
- 3947US2021363257A1Novel fusion protein specific for cd137 and pd-l1PIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Janet Peper files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →